June 10 (UPI) -- Moderna, Inc. announced Thursday it is approaching the Food and Drugs Administration for emergency use authorization for its COVID-19 vaccine in children 12 to 17.
The drug company said in May its studies showed its coronavirus vaccines were 96% effective in that age group. In its first-quarter earnings report last month, Moderna said teenagers tested showed no serious side effects after receiving the shot.